Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza a virus subtype h3n2 hemagglutinin recombinant
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant Influenza A virus subtype H3N2 haemagglutinin is the purified, laboratory-produced form of the viral surface glycoprotein hemagglutinin (HA) from the H3N2 strain of Influenza A. It is used as an active component in certain seasonal influenza vaccines to stimulate immunity against circulating H3N2 strains. The HA protein mediates viral entry by binding to sialic acid receptors on host cells and facilitating membrane fusion. Recombinant production allows for rapid and scalable vaccine manufacturing without using live or inactivated viruses. Flublok is a brand name for such vaccines containing this recombinant HA[7][8]. The primary indication is prevention of seasonal influenza caused by H3N2 strains.
- Brand names
- flublok
- Other names
- influenza a h3n2 hemagglutinin recombinantrecombinant h3n2 hemagglutininrecombinant influenza a virus h3n2 hemagglutinin protein
02
Targets
Sialoglycan (Cell-surface sialoglycan)
Beyond the preview
Go deeper on influenza a virus subtype h3n2 hemagglutinin recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza a virus subtype h3n2 hemagglutinin recombinant.